AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

AnaptysBio, Inc.NASDAQ: ANAB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $33.86M fell 17.8% year over year, ahead of the -23.4% change in trailing-twelve-month research & development. Sequentially, it rose 32.5% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Research & development amounted to 58.0% of revenue in FY2025, down 121.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -17.8% holds above the trailing-twelve-month pace of -23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.86M+32.5% QoQ
Last fiscal yearDec 2025
$135.97M-17.0% YoY
LTMMar 2026
$128.65M-23.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.8%——
1 year-17.0%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
135.97M USD
Year-over-year change
-17.0%
4-year CAGR
+8.4%

Research & Development vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 research & development of $128.65M is the 6th highest of the 10 companies compared; the peer median is $172.31M.
  • Its year-over-year change of -23.4% is the 9th highest of 10, against a peer median of +27.7%.
  • Research & development amounts to 55.4% of revenue for ANAB, versus a peer median of 3643.0%.
ANAB Competitors Peer median
Research & Development for ANAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$468.85M +16.2%+41.8%6608.2%
XNCRXencor, Inc.LTM Jun 2026$255.77M +11.4%+6.3%243.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$220.82M +62.1%+69.0%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$175.6M +66.9%+70.5%9222.6%
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M -23.4%+15.3%55.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M +27.7%+16.5%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M +60.6%-12.2%677.9%
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M +29.2%-26.9%59059.4%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M -66.4%-18.8%28.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $172.31M+27.7%+16.5%3643.0%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.18M10.29M17.16M91.28M234.6M
Cost of Revenue98.5M88.8M132.28M163.84M2.42M
Gross Profit(35.32M)(78.51M)(115.13M)(72.56M)232.18M
Gross Margin-55.9%-763.2%-671.0%-79.5%99.0%
Research & Development98.5M88.8M139.62M163.84M135.97M
Selling, General & Admin21.49M36.64M41.95M42.39M50.74M
Operating Expenses21.49M36.64M49.29M42.39M184.28M
Depreciation & Amortization2.09M2.34M652K2.4M2.42M
EBITDA(55.71M)(105.26M)(156.42M)(92.74M)69.25M
EBITDA Margin-88.2%-1023.2%-911.7%-101.6%29.5%
Operating Income(56.81M)(115.15M)(164.41M)(114.95M)47.9M
Operating Margin-89.9%-1119.4%-958.3%-125.9%20.4%
Interest Income431K7.55M18.87M19.79M13.5M
Interest Expense1.45M21.11M18.08M50.09M79.89M
Other Income / Expenses(982K)(13.55M)788K(30.28M)(60.96M)
Income Before Tax(57.8M)(128.7M)(163.62M)(145.23M)(13.07M)
Pre-Tax Margin-91.5%-1251.1%-953.7%-159.1%-5.6%
Income Tax Expense024K(4K)3K164K
Net Income(57.8M)(128.72M)(163.62M)(145.23M)(13.23M)
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (Basic)(2.11)(4.57)(6.08)(5.12)(0.46)
EPS (Diluted)(2.11)(4.57)(6.08)(5.12)(0.46)
Weighted Avg Shares27.43M28.17M26.92M28.38M27.79M
Weighted Avg Shares (Diluted)27.43M28.17M26.92M28.38M31.34M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.